Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation

Clinical and Experimental Medicine

Volumn 16, Issue 2, 2016, Pages 183-192

  Wang, Yanhong ^a   Tian, Jihua ^a   Guo, Haixiu ^a   Mi, Yang ^a   Zhang, Ruijing ^a   Li, Rongshan ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

IgA nephropathy; Inflammation; Intermedin; Oxidative stress

Indexed keywords

BETA ACTIN; COLLAGEN TYPE 4; GELATINASE B; INTERMEDIN; MALONALDEHYDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; ADRENOMEDULLIN; INTERMEDIN PROTEIN, RAT; NEUROPEPTIDE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; IMMUNE COMPLEX DEPOSITION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MONONUCLEAR CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; ANIMAL; GLOMERULONEPHRITIS, IGA; KIDNEY; PATHOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ADRENOMEDULLIN; ANIMALS; GLOMERULONEPHRITIS, IGA; INFLAMMATION; KIDNEY; MALE; NEUROPEPTIDES; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84928605132     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-015-0351-8     Document Type: Article

References (49)

1. D’Amico G. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36(2):227–37.
2. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347(10):738–48.
3. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29(4):526–32.
4. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analyses. Am J Kidney Dis. 1991;18(1):12–9.
5. Camilla R, Suzuki H, Dapra V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol. 2011;6:1903–11.
6. Chen JX, Zhou JF, Shen HC. Oxidative stress and damage induced by abnormal free radical reactions and IgA nephropathy. J Zhejiang Univ Sci B. 2005;6(1):61–8.
7. Kobori H, Katsurada A, Ozawa Y, et al. Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun. 2007;358(1):156–63.
8. Camilla R, Suzuki H, Dapra V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(8):1903–11.
9. Chan LY, Leung JC, Lai KN. Novel mechanisms of tubulointerstitial injury in IgA nephropathy: A new therapeutic paradigm in the prevention of progressive renal failure. Clin Exp Nephrol. 2004;8(4):297–303.
10. Kawasaki Y. The pathogenesis and treatment of IgA nephropathy. Fukushima J Med Sci. 2008;54(2):43–60.
11. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012;81(9):833–43.
12. Cichon MA, Radisky DC. ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-kB-dependent activation of Snail. Oncotarget. 2014;5(9):2827–38.
13. Long T, Liu G, Wang Y, Chen Y, Zhang Y, Qin D. TNF-alpha, erectile dysfunction, and NADPH oxidase-mediated ROS generation in corpus cavernosum in high-fat diet/streptozotocin-induced diabetic rats. J Sex Med. 2012;9(7):1801–14.
14. Yang SM, Ka SM, Hua KF, et al. Antroquinonol mitigates an accelerated and progressive IgA nephropathy model in mice by activating the Nrf2 pathway and inhibiting T cells and NLRP3 inflammasome. Free Radic Biol Med. 2013;61C:285–97.
15. Kastl L, Sauer SW, Ruppert T, et al. TNF-alpha mediates mitochondrial uncoupling and enhances ROS-dependent cell migration via NF-kappaB activation in liver cells. FEBS Lett. 2014;588(1):175–83.
16. Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem. 2004;279(8):7264–74.
17. Chang CL, Roh J, Hsu SY. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: A comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides. 2004;25(10):1633–42.
18. Takahashi K, Kikuchi K, Maruyama Y, et al. Immunocytochemical localization of adrenomedullin 2/intermedin-like immunoreactivity in human hypothalamus, heart and kidney. Peptides. 2006;27(6):1383–9.
19. Morimoto R, Satoh F, Murakami O, et al. Expression of adrenomedullin2/intermedin in human brain, heart, and kidney. Peptides. 2007;28(5):1095–103.
20. Li L, Ma P, Liu Y, et al. Intermedin attenuates LPS-induced inflammation in the rat testis. PLoS One. 2013;8(6):e65278.
21. Wang Y, Li R, Qiao X, et al. Intermedin/adrenomedullin 2 protects against tubular cell hypoxia-reoxygenation injury in vitro by promoting cell proliferation and upregulating cyclin D1 expression. Nephrology (Carlton). 2013;18(9):623–32.
22. Qiao X, Li RS, Li H, et al. Intermedin protects against renal ischemia-reperfusion injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2013;304(1):F112–9.
23. Zhao L, Peng DQ, Zhang J, et al. Extracellular signal-regulated kinase 1/2 activation is involved in intermedin1-53 attenuating myocardial oxidative stress injury induced by ischemia/reperfusion. Peptides. 2012;33(2):329–35.
24. Hagiwara M, Bledsoe G, Yang ZR, Smith RJ, Chao L, Chao J. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2008;295(6):F1735–43.
25. Li H, Bian Y, Zhang N, et al. Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats. Cardiovasc Diabetol. 2013;12(1):91.
26. Chen L, Kis B, Hashimoto H, et al. Adrenomedullin 2 protects rat cerebral endothelial cells from oxidative damage in vitro. Brain Res. 2006;1086(1):42–9.
27. Tian J, Wang Y, Liu X, Zhou X, Li R. Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms. Exp Biol Med (Maywood). 2014 [Epub ahead of print].
28. Tian J, Wang Y, Zhou X, et al. Rapamycin slows IgA nephropathy progression in the rat. Am J Nephrol. 2014;39(3):218–29.
29. Ohashi N, Urushihara M, Kobori H. Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy. Minerva Urol Nefrol. 2009;61(1):55–66.
30. Ohashi N, Katsurada A, Miyata K, et al. Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol. 2009;36(8):750–5.
31. Ashizawa M, Miyazaki M, Abe K, et al. Detection of nuclear factor-kappaB in IgA nephropathy using Southwestern histochemistry. Am J Kidney Dis. 2003;42(1):76–86.
32. Silva GE, Costa RS, Ravinal RC, et al. NF-kB expression in IgA nephropathy outcome. Dis Markers. 2011;31(1):9–15.
33. Dong F, Taylor MM, Samson WK, Ren J. Intermedin (adrenomedullin-2) enhances cardiac contractile function via a protein kinase C- and protein kinase A-dependent pathway in murine ventricular myocytes. J Appl Physiol. 2006;101(3):778–84.
34. Yang JH, Cai Y, Duan XH, et al. Intermedin 1-53 inhibits rat cardiac fibroblast activation induced by angiotensin II. Regul Pept. 2009;158(1–3):19–25.
35. Pan CS, Yang JH, Cai DY, et al. Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2. Peptides. 2005;26(9):1640–6.
36. Segarra A. Progress in understanding the pathogenesis of IgA nephropathy: New perspectives for the near future? Nefrologia. 2010;30(5):501–7.
37. Kobori H, Katsurada A, Ozawa Y, et al. Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun. 2007;358(1):156–63.
38. Vas T, Wagner Z, Jenei V, et al. Oxidative stress and non-enzymatic glycation in IgA nephropathy. Clin Nephrol. 2005;64(5):343–51.
39. Ohashi N, Katsurada A, Miyata K, et al. Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol. 2009;36(8):750–5.
40. Coppo R, Camilla R, Alfarano A, et al. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int. 2009;75(5):536–41.
41. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Early prediction of IgA nephropathy progression: Proteinuria and AOPP are strong prognostic markers. Kidney Int. 2004;66(4):1606–12.
42. Hua KF, Yang SM, Kao TY, et al. Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and NF-kappaB/NLRP3 pathway. PLoS One. 2013;8(10):e77794.
43. Roebuck KA. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: Differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med. 1999;4(3):223–30.
44. Yang SM, Ka SM, Hua KF, et al. Antroquinonol mitigates an accelerated and progressive IgA nephropathy model in mice by activating the Nrf2 pathway and inhibiting T cells and NLRP3 inflammasome. Free Radic Biol Med. 2013;61C:285–97.
45. Miki H, Funato Y. Regulation of intracellular signalling through cysteine oxidation by reactive oxygen species. J Biochem. 2012;151(3):255–61.
46. Loukili N, Rosenblatt-Velin N, Rolli J, et al. Oxidants positively or negatively regulate nuclear factor kappaB in a context-dependent manner. J Biol Chem. 2010;285(21):15746–52.
47. Ryan KA, Smith MJ, Sanders MK, Ernst PB. Reactive oxygen and nitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression. Infect Immun. 2004;72(4):2123–30.
48. Mori H, Kaneko Y, Narita I, et al. Monocyte chemoattractant protein-1 A-2518G gene polymorphism and renal survival of Japanese patients with immunoglobulin a nephropathy. Clin Exp Nephrol. 2005;9(4):297–303.
49. Torres DD, Rossini M, Manno C, et al. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 2008;73(3):327–33.